Archive · 1 Aug 2025
Broker Maintains Outperform Rating on Sun Pharma Stock
Sun Pharma's financial performance in Q1-FY26 showed positive trends, with revenue and US sales growing.
The company's earnings also improved.
A loss of ₹810 crore was reported due to impairment costs and a settlement agreement.
Despite the losses, analysts remain optimistic, as evidenced by the 'Outperform' rating, projecting future growth driven by global specialty business and domestic market performance.
Sun Pharma's Q1-FY26 revenue increased by 9.5% year-over-year.
US sales grew 2% quarter-over-quarter to $473 million, driven by specialty products.
EBITDA margin improved 250 bps year-over-year to 31.1%.
Sun Pharma incurred an exceptional loss of ₹810 crore.
Brokerage maintains an Outperform rating and sets a target price of ₹1,978.
- Who
- Sun Pharmaceutical Industries Ltd.
- What
- Sun Pharma's Q1-FY26 financial performance.
- When
- Q1-FY26 (Quarter 1 of fiscal year 2026).
- Where
- United States and India (Revenue)
- Why
- Driven by specialty products, domestic and RoW markets.
Factors Impacting Performance
Future Potential
Financial Outlook
Factors Impacting Performance
Impact of Exceptional loss.
Future Potential
Focus on growth through specialty products and domestic market
- CMP
- ₹1,629.05
- Target Price
- ₹1,978
- US Sales
- $473 million
- Revenue Growth
- 9.5% YoY
- EBITDA Margin Improvement
- 250 bps YoY
- Exceptional Loss
- ₹810 crore
Sources
Sun Pharma shares drop nearly 6% after Q1 earnings
Sun Pharma tanks 6% on weak Q1; Choice sees 11% upside; here’s target price
Sun Pharma shares fall 5.7% post Q1 results: What should investors do now?
NSE-listed pharma stock shows resilience despite weak trends in Indian stock market
Sun Pharma slides 6% but Motilal Oswal recommends Buy: 3 reasons why
Stocks making the biggest moves midday: Suzlon, Waaree Energies, PNB Housing Finance and more
Markets end weak as Trump tariff continue to weigh on sentiment, Nifty slides below 24,600; Pharma bleeds
Sensex tanks 585 pts, Nifty below 24,600; why stock market is losing steam